1
|
Alavi A, Pool AJ, Axford JS. New Insights into Rheumatoid Arthritis Associated Glycosylation Changes. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2005; 564:129-38. [PMID: 16400819 DOI: 10.1007/0-387-25515-x_23] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Azita Alavi
- Biochemistry and Immunology, Academic Unit for Musculoskeletal Disease, St Georges Hospital Med School, Cranmer Terrace, London SW17 0RE, UK
| | | | | |
Collapse
|
2
|
Alavi A, Axford J. Glycobiology of the rheumatic diseases: an update. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2004; 535:271-80. [PMID: 14714902 DOI: 10.1007/978-1-4615-0065-0_18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Affiliation(s)
- Azita Alavi
- Academic Unit for Musculoskeletal Diseases, St George's Hospital Medical School, London SW17 ORE, UK
| | | |
Collapse
|
3
|
Képès F, Rambourg A, Satiat-Jeunemaître B. Morphodynamics of the secretory pathway. INTERNATIONAL REVIEW OF CYTOLOGY 2004; 242:55-120. [PMID: 15598467 DOI: 10.1016/s0074-7696(04)42002-6] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
A careful scrutiny of the dynamics of secretory compartments in the entire eukaryotic world reveals many common themes. The most fundamental theme is that the Golgi apparatus and related structures appear as compartments formed by the act of transporting cargo. The second common theme is the pivotal importance for endomembrane dynamics of shifting back and forth the equilibrium between full and perforated cisternae along the pathway. The third theme is the role of a continuous membrane flow in anterograde transfer of molecules from the endoplasmic reticulum through the Golgi apparatus. The last common theme is the self-regulatory balance between anatomical continuities and discontinuities of the endomembrane system. As this balance depends on secretory activity, it provides a source of morphological variability among cell types or, for a given cell type, according to environmental conditions. Beyond this first source of variability, it appears that divergent strategies pave the evolutionary routes in different eukaryotic kingdoms. These divergent strategies primarily affect the levels of stacking, of stabilization, and of clustering of the Golgi apparatus. They presumably underscore a trade-off between versatility and stability to adapt the secretory function to the degree of environmental variability. Nonequilibrium secretory structures would provide yeasts, and plants to a lesser extent, with the required versatility to cope with ever changing environments, by contrast to the stabler milieu intérieur of homeothermic animals.
Collapse
Affiliation(s)
- François Képès
- ATelier de Génomique Cognitive, CNRS UMR 8071/Genopole and Epigenomics Project, Genopole, Evry, France
| | | | | |
Collapse
|
4
|
McCauley TC, Kurth BE, Norton EJ, Klotz KL, Westbrook VA, Rao AJ, Herr JC, Diekman AB. Analysis of a human sperm CD52 glycoform in primates: identification of an animal model for immunocontraceptive vaccine development. Biol Reprod 2002; 66:1681-8. [PMID: 12021047 DOI: 10.1095/biolreprod66.6.1681] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Sperm agglutination antigen-1 (SAGA-1) is a human male reproductive tract glycoform of CD52. Unique modification of CD52 N-linked oligosaccharide chains in the epididymis and vas deferens results in the appearance of a carbohydrate epitope that is localized over the entire surface of human spermatozoa. SAGA-1 was characterized by the sperm-inhibitory murine monoclonal antibody (mAb) S19, and it is the target antigen of a human mAb (H6-3C4) associated with antibody-mediated infertility. Collectively, sperm surface localization, antibody inhibition of sperm function, and potential reproductive-tissue specificity identify SAGA-1 as an attractive candidate contraceptive immunogen. To establish an animal model for the study of SAGA-1 in immunologic infertility and immunocontraceptive development, we investigated the appearance of the S19 carbohydrate epitope in nonhuman primates. The S19 mAb demonstrated little to no immunoreactivity by Western blot analysis with protein extracts of spermatozoa from the baboon, marmoset, bonnet, cynomolgus, and pigtailed macaques. Immunohistochemical analysis identified CD52 in the bonnet monkey epididymis; however, the N-linked carbohydrate moiety recognized by the S19 mAb, and unique to SAGA-1, was absent. In contrast, the S19 carbohydrate epitope was identified in chimpanzee sperm extracts by Western blot analysis and in chimpanzee epididymal tissue sections by immunohistochemical analysis, indicating that it is conserved in this close relative of the human. Chimpanzee testis, seminal vesicle, and prostate do not express the S19 epitope. Although anti-CD52 immunoreactivity was identified in the spleen, the carbohydrate moiety recognized by the S19 mAb was absent, corroborating data in the human that demonstrated tissue-specific glycosylation of sperm CD52. Immunofluorescent analysis indicated that the chimpanzee homologue of sperm CD52 was present over the entire spermatozoon. In addition, the S19 mAb agglutinated chimpanzee spermatozoa in a manner similar to the effect observed on human spermatozoa. These data indicate that the distinctive carbohydrate moiety of human sperm CD52 is present in the chimpanzee, and they identify the chimpanzee as the most appropriate primate model to study the potential of this unique CD52 glycoform as a contraceptive immunogen.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/immunology
- Antibodies, Monoclonal/pharmacology
- Antigens, CD/analysis
- Antigens, Neoplasm/analysis
- Antigens, Surface/analysis
- Antigens, Surface/immunology
- Biological Evolution
- Blotting, Western
- CD52 Antigen
- Callithrix/immunology
- Contraception, Immunologic
- Epididymis/immunology
- Epitopes/analysis
- Epitopes/chemistry
- Epitopes/immunology
- Fluorescent Antibody Technique
- Glycoproteins/analysis
- Glycoproteins/immunology
- Glycosylation
- Humans
- Immunohistochemistry
- Immunosorbent Techniques
- Macaca fascicularis/immunology
- Macaca nemestrina/immunology
- Macaca radiata/immunology
- Male
- Models, Animal
- Pan troglodytes/immunology
- Papio/immunology
- Species Specificity
- Spermatozoa/immunology
- Spermatozoa/physiology
- Vaccines, Contraceptive
Collapse
Affiliation(s)
- Tod C McCauley
- Department of Cell Biology, University of Virginia Health System, Charlottesville, Virginia 22908, USA
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Hays WS, VanderJagt DJ, Bose B, Serianni AS, Glew RH. Catalytic mechanism and specificity for hydrolysis and transglycosylation reactions of cytosolic beta-glucosidase from guinea pig liver. J Biol Chem 1998; 273:34941-8. [PMID: 9857024 DOI: 10.1074/jbc.273.52.34941] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Cytosolic beta-glucosidase (CBG) from mammalian liver is known for its broad substrate specificity and has been implicated in the transformation of xenobiotic glycosides. CBG also catalyzes a variety of transglycosylation reactions, which have been been shown with other glycosylhydrolases to function in synthetic and genetic regulatory pathways. We investigated the catalytic mechanism, substrate specificity, and transglycosylation acceptor specificity of guinea pig liver CBG by several methods. These studies indicate that CBG employs a two-step catalytic mechanism with the formation of a covalent enzyme-sugar intermediate and that CBG will transfer sugar residues to primary hydroxyls and equatorial but not axial C-4 hydroxyls of aldopyranosyl sugars. Kinetic studies revealed that correction for transglycosylation reactions is necessary to derive correct kinetic parameters for CBG. Further analyses revealed that for aldopyranosyl substrates, the activation energy barrier is affected most by the presence of a C-6 carbon and by the configuration of the C-2 hydroxyl, whereas the binding energy is affected modestly by the configuration and substituents at C-2, C-4, and C-5. These data indicate that the transglycosylation activity of CBG derives from the formation of a covalently linked enzyme-sugar intermediate and that the specificity of CBG for transglycosylation reactions is different from its specificity for hydrolysis reactions.
Collapse
Affiliation(s)
- W S Hays
- Department of Biochemistry and Molecular Biology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131, USA
| | | | | | | | | |
Collapse
|
6
|
Raju TS, Stanley P. Gain-of-function Chinese hamster ovary mutants LEC18 and LEC14 each express a novel N-acetylglucosaminyltransferase activity. J Biol Chem 1998; 273:14090-8. [PMID: 9603907 DOI: 10.1074/jbc.273.23.14090] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
LEC18 and LEC14 cells are gain-of-function glycosylation mutants isolated from Chinese hamster ovary cells for resistance to pea lectin. Structural studies have shown that LEC18 cells synthesize complex N-glycans with a GlcNAc residue linked at the O-6 position of the core GlcNAc (Raju, T. S., Ray, M. K., and Stanley, P. (1995) J. Biol. Chem. 270, 30294-30302), whereas LEC14 cells synthesize complex N-glycans with a GlcNAc residue linked at the O-2 position of the core beta-linked Man residue (Raju, T. S., and Stanley, P. (1996) J. Biol. Chem. 271, 7484-7493). Both modifications are novel and have not been reported in glycoproteins from any other source. We now show that, in both LEC18 and LEC14 cells, GlcNAc transfer is mediated by a distinct N-acetylglucosaminyltransferase (GlcNAc-T) activity. The LEC18 activity, termed GlcNAc-TVIII, transfers GlcNAc to GlcNAcbeta1-O-pNP and to a GlcNAc-terminating, biantennary, complex N-glycan, with or without a core fucose. By contrast, the LEC14 transferase, termed GlcNAc-TVII, does not have significant activity with simple acceptors, and transfers GlcNAc preferentially to a GlcNAc-terminating biantennary glycopeptide that contains a core fucose residue. The acceptor specificities and other biochemical properties of GlcNAc-TVII and GlcNAc-TVIII differ from previously characterized GlcNAc-transferases including GlcNAc-TIII, indicating that they represent new members of the mammalian GlcNAc-T group of transferases.
Collapse
Affiliation(s)
- T S Raju
- Department of Cell Biology, Albert Einstein College of Medicine, New York, New York 10461, USA
| | | |
Collapse
|
7
|
Yki-Järvinen H, Virkamäki A, Daniels MC, McClain D, Gottschalk WK. Insulin and glucosamine infusions increase O-linked N-acetyl-glucosamine in skeletal muscle proteins in vivo. Metabolism 1998; 47:449-55. [PMID: 9550544 DOI: 10.1016/s0026-0495(98)90058-0] [Citation(s) in RCA: 92] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
O-linked N-acetylglucosamine (O-GlcNAc) is an abundant posttranslational modification of serine/threonine residues of nuclear and cytoplasmic proteins. We determined whether insulin or coinfusion of glucosamine (GlcN) with insulin alters O-GlcNAc of skeletal muscle proteins. Three groups of conscious fasted rats received 6-hour infusions of either saline (BAS), insulin 18 mU/kg.min and saline (INS), or insulin and GlcN 30 micromol/kg.min (GLCN) during maintenance of normoglycemia. At 6 hours, the concentrations of muscle UDP-GlcNAc, UDP-N-acetylgalactosamine (UDP-GalNAc), UDP-glucose (UDP-Glc), UDP-galactose (UDP-Gal), glycogen, and N and O-linked GlcNAc (galactosyltransferase labeling followed by beta elimination) were measured in freeze-clamped abdominis muscle. Insulin increased whole-body glucose uptake from 49 +/- 5 to 239 +/- 8 micromol/kg.min (P < .001) and glycogen in abdominis muscle from 138 +/- 11 to 370 +/- 26 mmol/kg dry weight (P < .001). Insulin increased the amount of cytosolic N - and O-linked GlcNAc by 56% from 362 +/- 30 to 564 +/- 45 dpm/microg protein . 100 min (P < .02), and O-GlcNAc from 221 +/- 16 to 339 +/- 27 dpm/microg . 100 min (P < .02). Glycogen content was positively correlated with the amount of total (r = .90, P < .005) and O-linked GlcNAc in insulin-infused animals. Coinfusion of GlcN with insulin increased muscle UDP-GlcNAc about fourfold (100 +/- 6 nmol/g) compared with insulin (27 +/- 1, P < .001) or saline (25 +/- 1, P < .001) infusion. GlcN also decreased glucose uptake over 6 hours by 30% to 168 +/- 8 micromol/kg . min (P < .001 for GLCN v INS) and muscle glycogen to 292 +/- 24 mmol/kg dry weight (P < .05 for GLCN v INS). Both total (635 +/- 60 dpm/microg . 100 min, P < .002) and O-linked GlcNAc (375 +/- 36 dpm/microg . 100 min, P < .002) in the cytosol were significantly higher in GLCN rats (635 +/- 60 dpm/microg) versus BAS rats (P < .002). As in INS rats, muscle glycogen and O-GlcNAc were positively correlated in GLCN rats (r = .54, P < .05). Variation in total and O-linked GlcNAc in GLCN rats was due both to GlcN (P < .02) and to variation in the glycogen content (P < .005).
Collapse
Affiliation(s)
- H Yki-Järvinen
- Department of Medicine, University of Texas Health Science Center at San Antonio, USA
| | | | | | | | | |
Collapse
|
8
|
Kolbinger F, Streiff MB, Katopodis AG. Cloning of a human UDP-galactose:2-acetamido-2-deoxy-D-glucose 3beta-galactosyltransferase catalyzing the formation of type 1 chains. J Biol Chem 1998; 273:433-40. [PMID: 9417100 DOI: 10.1074/jbc.273.1.433] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Biochemical evidence suggests that the galactosyltransferase activity synthesizing type 1 carbohydrate chains is separate from the well characterized enzyme that is responsible for the synthesis of type 2 chains. This was recently confirmed by the cloning, from melanoma cells, of an enzyme capable of synthesizing type 1 chains, which was shown to have no homology to other galactosyltransferases. We report here the molecular cloning and functional expression of a second human beta3-galactosyltransferase distinct from the melanoma enzyme. The new beta3-galactosyltransferase has homology to the melanoma enzyme in the putative catalytic domain, but has longer cytoplasmic and stem regions and a carboxyl-terminal extension. Northern blots showed that the new gene is present primarily in brain and heart. When transfected into mammalian cells, this gene directs the synthesis of type 1 chains as determined by a monoclonal antibody specific for sialyl Lewisa. A soluble version of the cloned enzyme was expressed in insect cells and purified. The soluble enzyme readily catalyzes the transfer of galactose to GlcNAc to form Gal(beta1-3)GlcNAc. It also has a minor but distinct transfer activity toward Gal, LacNAc, and lactose, but is inactive toward GalNAc.
Collapse
Affiliation(s)
- F Kolbinger
- Novartis Pharma AG, Transplantation Preclinical Research, CH 4002 Basel, Switzerland
| | | | | |
Collapse
|
9
|
Suzuki M, Inufusa H, Yamamoto S, Hamada T, Aga M, Ando O, Ohta T, Yasutomi M, Kurimoto M. Le(y) glycolipid acts as a co-factor for tumor procoagulant activity. Int J Cancer 1997; 73:903-9. [PMID: 9399674 DOI: 10.1002/(sici)1097-0215(19971210)73:6<903::aid-ijc24>3.0.co;2-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We have generated a monoclonal antibody (MAb), FS01, which inhibits the procoagulant activity (CCA-1) produced by a human squamous cell carcinoma cell line, LK52. Expression of the antigen recognized by FS01 MAb in various cancer cell lines correlated well with the procoagulant activities of the expressing cell lines. Our objective was to characterize the molecule reacting with FS01 MAb and to analyze its involvement in the CCA-1 procoagulant activity. The molecule was identified as a glycolipid and found to be involved in the procoagulant activity because both procoagulant activity and reactivity to FS01 MAb were lost after endoglycoceramidase treatment of CCA-1. Furthermore, FS01 MAb recognized the Lewis Y (Le[y]) antigen. To confirm the involvement of a glycolipid incorporating the Le(y) antigen in the procoagulant activity, we attempted to purify CCA-1 from LK52 culture supernatant. In one of the purification steps, a fraction containing low procoagulant activity (CCA-1p) separated from the Le(y)-positive fraction (CCA-1c). Although CCA-1c alone did not show procoagulant activity, the procoagulant activity of CCA-1p was augmented by CCA-1c and this augmentation was inhibited by FS01 MAb. Furthermore, CCA-1c enhanced the procoagulant activity of 33 cell lines tested as well as CCA-1p. In addition, purified Le(y) glycolipid from canine intestine augmented the procoagulant activity of CCA-1p, and this augmentation also could be inhibited by FS01 MAb. We conclude that Le(y) glycolipid is a co-factor for the procoagulant activity derived from cancer cells.
Collapse
Affiliation(s)
- M Suzuki
- Fujisaki Institute, Hayashibara Biochemical Laboratories Inc., Okayama, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Srikrishna G, Varki NM, Newell PC, Varki A, Freeze HH. An IgG monoclonal antibody against Dictyostelium discoideum glycoproteins specifically recognizes Fucalpha1,6GlcNAcbeta in the core of N-linked glycans. Localized expression of core-fucosylated glycoconjugates in human tissues. J Biol Chem 1997; 272:25743-52. [PMID: 9325301 DOI: 10.1074/jbc.272.41.25743] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Core fucosylation of N-linked oligosaccharides (GlcNAcbeta1, 4(Fucalpha1,6)GlcNAcbeta1-Asn) is a common modification in animal glycans, but little is known about the distribution of core-fucosylated glycoproteins in mammalian tissues. Two monoclonal antibodies, CAB2 and CAB4, previously raised against carbohydrate epitopes of Dictyostelium discoideum glycoproteins (Crandall, I. E. and Newell, P. C. (1989) Development 107, 87-94), specifically recognize fucose residues in alpha1,6-linkage to the asparagine-bound GlcNAc of N-linked oligosaccharides. These IgG3 antibodies do not cross-react with glycoproteins containing alpha-fucoses in other linkages commonly seen in N- or O-linked sugar chains. CAB4 recognizes core alpha1,6 fucose regardless of terminal sugars, branching pattern, sialic acid linkage, or polylactosamine substitution. This contrasts to lentil and pea lectins that recognize a similar epitope in only a subset of these structures. Additional GlcNAc residues found in the core of N-glycans from dominant Chinese hamster ovary cell mutants LEC14 and LEC18 progressively decrease binding. These antibodies show that many proteins in human tissues are core-fucosylated, but their expression is localized to skin keratinocytes, vascular and visceral smooth muscle cells, epithelia, and some extracellular matrix-like material surrounding subpopulations of lymphocytes. The availability of these antibodies now allows for an extended investigation of core fucose epitope expression in development and malignancy and in genetically manipulated mice.
Collapse
Affiliation(s)
- G Srikrishna
- Burnham Institute, La Jolla, California 92037, USA
| | | | | | | | | |
Collapse
|
11
|
Elling L. Glycobiotechnology: enzymes for the synthesis of nucleotide sugars. ADVANCES IN BIOCHEMICAL ENGINEERING/BIOTECHNOLOGY 1997; 58:89-144. [PMID: 9103912 DOI: 10.1007/bfb0103303] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Complex carbohydrates, as constituting part of glycoconjugates such as glycoproteins, glycolipids, hormones, antibiotics and other secondary metabolites, play an active role in inter- and intracellular communication. The aim of "glycobiotechnology" as an upcoming interdisciplinary research field is to develop highly efficient synthesis strategies, including in vivo and in vitro approaches, in order to bring such complex molecules into analytical and therapeutic studies. The enzymatic synthesis of glycosidic bonds by Leloir-glycosyltransferases is an efficient strategy for obtaining saccharides with absolute stereo- and regioselectivity in high yields and under mild conditions. There are, however, two obstacles hindering the realization of this process on a biotechnological scale, namely the production of recombinant Leloir-glycosyltransferases and the availability of enzymes for the synthesis of nucleotide sugars (the glycosyltransferase donor substrates). The present review surveys some synthetic targets which have attracted the interest of glycobiologists as well as recombinant expression systems which give Leloir-glycosyltransferase activities in the mU and U range. The main part summarizes publications concerned with the complex pathways of primary and secondary nucleotide sugars and the availability and use of these enzymes for synthesis applications. In this context, a survey of our work will demonstrate how enzymes from different sources and pathways can be combined for the synthesis of nucleotide deoxysugars and oligosaccharides.
Collapse
Affiliation(s)
- L Elling
- Institut für Enzymtechnologie, Heinrich-Heine-Universität Düsseldorf im Forschungszentrum Jülich, Germany
| |
Collapse
|
12
|
|